Atrys generates 212.7 million euros in revenues in 2024 and increases its EBITDA by 13.8% to 48.5 million euros

- *The company increases its turnover by 5.5% compared to 2023, 7.2% at constant exchange rates, driven by growth in all its business areas*
- *Adjusted EBITDA continues to grow strongly, up 13.8% to €48.5m and adjusted operating cash flow up 20.1%*
- *The company reduced its consolidated loss by 31% to €31.7m at the end of the year*

28 DE MARZO DE 2025.– Atrys, a global healthtech company providing precision medical prevention, diagnosis and treatment services and a leader in telemedicine and oncology treatment, has announced its 2024 results, which reflect organic growth with revenues of EUR 212.7 million, up 5.5% on 2023 (7.2% at constant exchange rates), and adjusted EBITDA continuing to grow significantly (13.8%) to EUR 48.5 million.

Gross margin increased by 2% to €140m, while adjusted operating cash flow grew by 20.1% to €35.3m.

Gross debt for the year is reduced by 4.3% to €191m and the leverage ratio (net financial debt to EBITDA) is reduced from 3.6x to 3.29x in FY2024.

Santiago de Torres, executive president of Atrys, said: 'These results reflect the strength and efficiency of our business model. All our business lines are performing well in terms of both revenue and EBITDA, demonstrating our ability to generate sustained and profitable value. Improved EBITDA and reduced leverage provide us with a solid foundation to confidently implement our long-term growth and consolidation strategy'.

Growth in all its business areas

Atrys continues to boost growth in its business lines - prevention, diagnostics and oncology - both in Spain and Latin America. Specifically, the company's turnover in the Spanish market grew by 4% to 156 million euros. In Portugal, turnover amounted to 15 million euros, 7% more than in 2023. In the Latin American market, Atrys' turnover grew by 11.6% to 42 million euros.

By areas of activity, in the **Prevention** segment, the area with the greatest weight in turnover, the company achieved a 4.4% increase in revenues, to €82.8m.

Turnover in the **Diagnostics** segment grew by 3.5% to €66.9m, which at constant exchange rates would represent an increase of 9.2%.

Finally, Atrys' **Oncology** division led growth with revenues of €63m, 9.5% higher than in the same period last year, driven mainly by activity in Mexico.

About Atrys

Atrys is a global healthtech company providing medical services that maximise efficiency in prevention, diagnosis and precision medical treatment through innovative technologies. It is a leader in telemedicine, oncology treatment and occupational risk prevention. It has a team of more than 2,000 professionals, is present in seven countries in Europe and Latin America, and is the only listed company in the healthcare technology sector in Spain. The company structures its activity around two main business areas, precision medicine and preventive medicine. The precision medicine area comprises diagnostics (telemedicine, nuclear medicine, pathology and molecular anatomy) and oncology treatment (medical oncology and advanced radiotherapy), while the preventive medicine area focuses on prevention and health promotion, serving more than one million people through ASPY's network of more than 200 offices throughout Spain.

Media contact

Diana Barriga	Almudena Guerra
Atrys	Roman
dbarriga@atryshealth.com	a.guerra@romanrm.com
+34 649 042 525	+34 659 215 222